PharmaBoardroom

Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how…

Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the…

We last met with you as the head of Zuellig in 2009. Obviously, a lot has changed since then; from both a sector and corporate point of view, what…

Deloitte is certainly renowned for its strong network of international expertise in the field of life sciences having teams in all of the crucial…

Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what…

Historically, Belgium is widely recognized as a major regional hub for clinical development. How would you compare the current environment to 1999,…

An in-depth viewpoint on the current taxation situation for pharmaceutical companies operating in Belgium today, looking at incentive programs and…

Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where…

Donald Niesten and Omer Saka discuss the current dynamics of the healthcare and pharmaceutical sectors in Belgium, the challenges of entering the…

2012 marks the twentieth anniversary of Polymun. Can you describe to our readers the origins of the company and how it compares to your expectations…

Would you begin by outlining the role & importance of George Clinical within the George Institute, highlighting recent milestones &…

HSA celebrated its 10th anniversary in 2011. How different is the organisation today from when it started? HSA covers the regulation of health…